Your payment is in progress...

Pseudomonal Infections - Pipeline Insight, 2022

Published on: Apr 2022 | From USD $1500 | Published By: DELVE INSIGHTS | Number Of Pages: 50

“Pseudomonal Infections- Pipeline Insight, 2022,” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Pseudomonal Infections pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
• Global coverage
Pseudomonal Infections Understanding

Pseudomonal Infections: Overview
Pseudomonas infections are diseases caused by a bacterium from the genus Pseudomonas. The bacteria are found widely in the environment, such as in soil, water, and plants. They usually do not cause infections in healthy people. If an infection does occur in a healthy person, it is generally mild. More severe infections occur in people who are already hospitalized with another illness or condition, or people who have a weak immune system. Pseudomonades are fairly common pathogens involved in infections acquired in a hospital setting. Infections in the skin tend to be less severe than infections that occur in the blood or lungs. Specific symptoms depend on where the infection occurs: A bacterial infection of the blood is called bacteremia. A blood infection is one of the most severe infections caused by pseudomonas. Symptoms may include: fever, chills, fatigue, muscle and joint pain. Bacteremia with pseudomonas can also cause very low blood pressure, known as hemodynamic shock, which can lead to failure of other organs including the heart, kidneys, and liver. When this bacterium infects the skin, it most often affects the hair follicles. This is called folliculitis. Symptoms may include: redness of the skin, abscess formation in the skin and draining wounds. Pseudomonas infections can be very aggressive, particularly infections in the lungs or skin. Pseudomonas infections are caused by a free-living bacterium from the genus Pseudomonas. They favor moist areas and are widely found in soil and water. Only a few of the many species cause disease. The most common species that causes infection is called Pseudomonas aeruginosa. Healthy people are usually at low risk of infection. People who already have a weakened immune system because of another illness or condition are at a higher risk of infection. This is especially true for people who are hospitalized for an extended period of time. Pseudomonas infections are treated with antibiotics. Unfortunately, many pseudomonas infections are becoming more difficult to treat. These bacteria have developed the ability to adapt and overcome antibiotics in their environment. This is called antibiotic resistance. The increase in antibiotic resistance has made treating infections much more challenging. Pseudomonas infections can often develop resistance to multiple types of antibiotics. It can even sometimes develop resistance during the course of treatment.

"Pseudomonal Infections- Pipeline Insight, 2022" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Pseudomonal Infections pipeline landscape is provided which includes the disease overview and Pseudomonal Infections treatment guidelines. The assessment part of the report embraces, in depth Pseudomonal Infections commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Pseudomonal Infections collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights
• The companies and academics are working to assess challenges and seek opportunities that could influence Pseudomonal Infections R&D. The therapies under development are focused on novel approaches to treat/improve Pseudomonal Infections.

Pseudomonal Infections Emerging Drugs Chapters
This segment of the Pseudomonal Infections report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Pseudomonal Infections Emerging Drugs
• AP-PA02: Armata Pharmaceuticals
AP-PA02 is a therapeutic phage cocktail that targets the pathogen P. aeruginosa, to treat serious respiratory infections, with an initial emphasis on cystic fibrosis (CF) patients. AP-PA02 is comprised of a cocktail of complementary P. aeruginosa phages that offer improved host range, increased potency, and aid in preventing the development of resistance. The drug is in Phase I b/II clinical trial studies.

• AB569: Arch Biopartners
AB569 constitutes an innovative method and potential candidate to treat mucoid and non mucoid P. aeruginosa pulmonary infections, as well as other types of bacterial pulmonary infections, that are resistant to traditional antibiotics. AB569 has potential to be modified for use in other indications, including adaptation as a topical cream for bacterial skin infections. AB569 has orphan drug status from the US FDA for the treatment of Pseudomonas aeruginosa infections in the respiratory tracts of patients with cystic fibrosis. AB569 also has orphan medicinal product designation from the European Medicines Agency for the treatment of cystic fibrosis. The drug is in Phase I clinical studies for the treatment of bacterial infections and pseudomonal infections.

• BX 004 : BiomX
BX004, a phage therapy for CF patients with chronic Pseudomonas aeruginosa (P. aeruginosa) respiratory infections, a main contributor to morbidity and mortality in this disease. Phase 1b/2a clinical study in CF patients is composed of two parts. Results from Part 1 aimed to evaluate the safety, pharmacokinetics, and microbiologic/clinical activity are expected in Q2 of 2022. Results from Part 2 aimed to demonstrate safety and efficacy are expected by Q3 of 2022.



• ETX 0462 : Entasis Therapeutics
ETX0462 is a novel, first-in-class, diazabicyclooctane with antimicrobial activity against multidrug-resistant (MDR) Gram-negative and biothreat pathogens including, P. aeruginosa, K. pneumoniae, S. maltophilia, E. coli, B. anthracis, Y. pestis, F. tularensis and Burkholderia spp. Similar to β-lactam antibiotics, ETX0462 inhibits penicillin-binding proteins which are essential for bacterial cell wall biosynthesis, however, unlike β-lactam antibiotics, ETX0462 is unaffected by β-lactamase mediated resistance. ETX0462 is supported by CARB. Currently the drug is in Pre-Clinical stage of development for the treatment of Pseudomonal infections.

Further product details are provided in the report……..

Pseudomonal Infections: Therapeutic Assessment
This segment of the report provides insights about the different Pseudomonal Infections drugs segregated based on following parameters that define the scope of the report, such as:
• Major Players in Pseudomonal Infections
There are approx. 15+ key companies which are developing the therapies for Pseudomonal Infections. The companies which have their Pseudomonal Infections drug candidates in the most advanced stage, i.e. phase I/II include, Armata Pharmaceuticals.
• Phases
DelveInsight’s report covers around 15+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

• Route of Administration
Pseudomonal Infections pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal
• Molecule Type

Products have been categorized under various Molecule types such as
• Oligonucleotide
• Peptide
• Small molecule
• Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Pseudomonal Infections: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Pseudomonal Infections therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Pseudomonal Infections drugs.

Pseudomonal Infections Report Insights
• Pseudomonal Infections Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs
Pseudomonal Infections Report Assessment
• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions
Current Treatment Scenario and Emerging Therapies:
• How many companies are developing Pseudomonal Infections drugs?
• How many Pseudomonal Infections drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Pseudomonal Infections?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Pseudomonal Infections therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Pseudomonal Infections and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players
• BiomX
• Zambon
• Polyphor
• Aridis Pharmaceuticals
• Armata Pharmaceuticals
• Arch Biopartners
• ContraFect
• AGILeBiotics
• ANTABIO

Key Products
• BX004
• AP-PA-02
• ABP-569
• ETX-0462
• ZP 044
• CF-370
• Murepavadin
• ABX 02

Introduction
Executive Summary
Pseudomonal Infections: Overview
• Causes
• Mechanism of Action
• Signs and Symptoms
• Diagnosis
• Disease Management
Pipeline Therapeutics
• Comparative Analysis
Therapeutic Assessment
• Assessment by Product Type
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type
Pseudomonal Infections– DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
• Comparative Analysis
Drug Name : Company Name
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase I/II)
• Comparative Analysis
AP-PA02: Armata Pharmaceuticals
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..

Early Stage Products (Phase I)
• Comparative Analysis
AB569: Arch Biopartners
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
• Comparative Analysis
ETX 0462 : Entasis Therapeutics
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..

Inactive Products
• Comparative Analysis
Pseudomonal Infections Key Companies
Pseudomonal Infections Key Products
Pseudomonal Infections- Unmet Needs
Pseudomonal Infections- Market Drivers and Barriers
Pseudomonal Infections- Future Perspectives and Conclusion
Pseudomonal Infections Analyst Views
Pseudomonal Infections Key Companies
Appendix

Table 1 Total Products for Pseudomonal Infections
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products


Figure 1 Total Products for Pseudomonal Infections
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products

SECONDARY RESEARCH
Secondary Research Information is collected from a number of publicly available as well as paid databases. Public sources involve publications by different associations and governments, annual reports and statements of companies, white papers and research publications by recognized industry experts and renowned academia etc. Paid data sources include third party authentic industry databases.

PRIMARY RESEARCH
Once data collection is done through secondary research, primary interviews are conducted with different stakeholders across the value chain like manufacturers, distributors, ingredient/input suppliers, end customers and other key opinion leaders of the industry. Primary research is used both to validate the data points obtained from secondary research and to fill in the data gaps after secondary research.

MARKET ENGINEERING
The market engineering phase involves analyzing the data collected, market breakdown and forecasting. Macroeconomic indicators and bottom-up and top-down approaches are used to arrive at a complete set of data points that give way to valuable qualitative and quantitative insights. Each data point is verified by the process of data triangulation to validate the numbers and arrive at close estimates.

EXPERT VALIDATION
The market engineered data is verified and validated by a number of experts, both in-house and external.

REPORT WRITING/ PRESENTATION
After the data is curated by the mentioned highly sophisticated process, the analysts begin to write the report. Garnering insights from data and forecasts, insights are drawn to visualize the entire ecosystem in a single report.

FAQs

Market research is a defined process to collect information about customers, competitors, and everything that a business needs to understand to sustain and grow. It offers important analysis to distinguish and examine the market needs, size, and trends. Market research is generally divided into, primary research and/or secondary research.

The process usually includes collection and interpretation of market data by using statistical and analytical techniques to support the decision making process.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Market research reports provide in-depth analysis about the market conditions and requirements for effective decision making.
The report provides a snapshot of the global market size, segmentation data, marketing growth strategies, market share, export and import information, analysis and forecast of market trends, competition, domestic production, best sales prospects, statistical data, tariffs, regulations, distribution and business practices, end-user analysis, contact points and more.

These research reports include information about competitive strategies, solutions, fact-based research, key takeaways, recommendations, market considerations, emerging business models and market opportunities for multiple segments of an industry.

Market research reports assist in solving business problems and making better decisions to improve business as per the prevalent market trends.
When you place an order with MarketInsightsReports, we try our best to deliver the product as soon as possible. The report will be delivered to you either by email or by physical delivery. If it’s delivered by email the order will be dispatched on the same working day or on the next working day of receipt of payment (unless otherwise specified on our website). There may be exceptions to this if you place order on a non-working day specifically because our publisher partners are located all over the globe. In case of physical delivery report will be couriered to you within 3 working days from the date of the receipt of payment and delivery time will differ based on your location

Any person who has the capacity to make decisions for the business must buy the reports. These reports help management in decision making process. Market research helps person to obtain market information from different sources, and in multiple formats. It aims to study supply and demand, analyze data as per geography, age factors, demography, technology, product, psychographic & gender differences, and many other parameters. Access to in-depth market trends helps person to assess the market effectiveness. Some of the multiple techniques used for market research include customer analysis, choice modeling, competition and risk analysis, product research, advertising the research, marketing mix modeling, simulated test marketing, and more.
Market research studies several features of business environment, such as competitors, market structure, government regulations, economic trends, technological advances and financial analysis of companies, industries, and sectors. This helps person in the decision-making process of planning and implementing strategies for their markets.

The generation of research report is concerned by most clients when purchasing it. Following general steps are taken for generating reports.
1. Choose a topic.
2. Make skeleton catalogue.
3. Fill content. As for report content, there are two main information source, Primary and Secondary data collection. Secondary data collectionrefers to information searched from the Internet or data bought from database. Primary data collection refers to information concluded from telephone interview, face-to-face interview, expert’s interview, meeting etc.
4. Audit the report
5. Publish the report.

With regard to information cost, information searching costs the least, database support the second least, and telephone interview the third least. Face-face interview cost higher, in-depth interview much higher and expert interview the highest. A research may adopt all of these approaches, or just some of them.
In general, a good-quality research report needs 1-3 months to be finished. Time and method varies according to different Publishers. Thus, it’s difficult to define an exact procedure or process of making research report. Both time and cost vary. However, specialization has become a basic industry standard. Professional and dedicated products will be more and more popular.
MarketInsightsReports has focused on various fields such as Life Science, IT, Telecommunication, Food& Beverages, Energy & Power, Automotive & Transportation, Materials& Chemicals, Financial Services and many more. These market research reports are available for all regions around the globe.
When you place an order with MarketInsightsReports, we try our best to deliver the product as soon as possible. The report will be delivered to you either by email or by physical delivery. If it’s delivered by email the order will be dispatched on the same working day or on the next working day of receipt of payment (unless otherwise specified on our website).

There may be exceptions to this if you place order on a non-working day specifically because our publisher partners are located all over the globe. In case of physical delivery report will be couriered to you within 3 working days from the date of the receipt of payment and delivery time will differ based on your location

Please Choose License Type

USD $1500
USD $3000
USD $4500
Offer

Why Us

  • Why Us In-depth database
    Our Report’s database covers almost all topics of all regions over the Globe..
  • Recognised publishing sources Recognised publishing sources
    Tie ups with top publishers around the globe.
  • Customer Support Customer Support
    Complete pre and post sales support.
  • Safe & Secure Safe & Secure
    Complete secure payment process.